Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	IPO	Follow-on Offering	Convertible Preferred Stock	Series B Convertible Preferred Stock	Common Stock	Common Stock IPO	Common Stock Follow-on Offering	Additional Paid-in Capital	Additional Paid-in Capital IPO	Additional Paid-in Capital Follow-on Offering	Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning balance at Dec. 31, 2018				$ 309,137
Beginning balance (in shares) at Dec. 31, 2018				69,910,520
Beginning balance at Dec. 31, 2018	$ (179,177)					$ 1			$ 14,672			$ (14)	$ (193,836)
Beginning balance (in shares) at Dec. 31, 2018						8,858,799
Issuance of convertible preferred stock, net of issuance cost (in Shares)					18,202,213
Beginning balance at Dec. 31, 2018				$ 309,137
Beginning balance (in shares) at Dec. 31, 2018				69,910,520
Beginning balance at Dec. 31, 2018	(179,177)					$ 1			14,672			(14)	(193,836)
Beginning balance (in shares) at Dec. 31, 2018						8,858,799
Issuance of convertible preferred stock, net of issuance cost					$ 327,475
Issuance of convertible preferred stock, net of issuance cost (in Shares)					18,202,213
Conversion of convertible preferred stock into common stock	636,612					$ 9			636,603
Conversion of convertible preferred stock into common (in shares)				(88,112,733)
Conversion of convertible preferred stock into common stock				$ (636,612)
Conversion of convertible preferred stock into common stock (in shares)						88,112,733
Issuance of common stock		$ 126,411					$ 1			$ 126,410
Issuance of common stock (in shares)							7,142,858
Reclassification of warrant liability to additional paid-in capital	3,073								3,073
Settlement of fractional shares from reverse stock split	(3)								(3)
Issuance of common stock in connection with a license agreement	617								617
Issuance of common stock in connection with a license agreement (in shares)						38,888
Repayment of promissory notes, net of unvested shares	1,355								1,355
Repayment of promissory notes, net of unvested shares (in shares)						1,390,925
Vesting of restricted common stock	476								476
Vesting of restricted common stock (in shares)						1,348,297
Exercise of stock options	1,129								1,129
Exercise of stock option (in shares)						756,425
Stock-based compensation	8,719								8,719
Other comprehensive loss	(587)											(587)
Net income (loss)	(174,683)												(174,683)
Ending balance at Dec. 31, 2019	423,942					$ 11			793,051			(601)	(368,519)
Ending balance (in shares) at Dec. 31, 2019						107,648,925
Issuance of convertible preferred stock, net of issuance cost (in Shares)					18,202,213
Reclassification of derivative liability to addition paid-in-capital	29,245								29,245
Issuance of common stock in connection with the achievement of a milestone (in shares)						1,111,111
Issuance of common stock in connection with a collaboration agreement	206,699					$ 1			206,698
Issuance of common stock in connection with a collaboration agreement (in shares)						6,626,027
Issuance of common stock for cashless exercise of warrant (in shares)						211,774
Issuance of common stock			$ 323,214					$ 1			$ 323,213
Issuance of common stock (in shares)								8,214,285
Vesting of restricted common stock	1,435								1,435
Vesting of restricted common stock (in shares)						1,986,250
Exercise of stock options	4,059								4,059
Exercise of stock option (in shares)						1,618,368
Stock-based compensation	27,600								27,600
Other comprehensive loss	(677)											(677)
Net income (loss)	(298,665)												(298,665)
Ending balance at Dec. 31, 2020	$ 716,852					$ 13			1,385,301			(1,278)	(667,184)
Ending balance (in shares) at Dec. 31, 2020	127,416,740					127,416,740
Issuance of common stock in connection with a collaboration agreement	$ 85,213								85,213
Issuance of common stock in connection with a collaboration agreement (in shares)						1,924,927
Issuance of common stock to settle a contingent consideration	1,860								1,860
Issuance of common stock to settle a contingent consideration (in shares)						42,737
Vesting of restricted common stock (in shares)						89,261
Exercise of stock options	13,077								13,077
Exercise of stock option (in shares)						1,622,718
Issuance of common stock under employee stock purchase plan	2,300								2,300
Issuance of common stock under employee stock purchase plan (in shares)						65,021
Stock-based compensation	83,784								83,784
Other comprehensive loss	179											179
Net income (loss)	528,584												528,584
Ending balance at Dec. 31, 2021	$ 1,431,849					$ 13			$ 1,571,535			$ (1,099)	$ (138,600)
Ending balance (in shares) at Dec. 31, 2021	131,161,404					131,161,404